StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC)

Equities researchers at StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note issued on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently weighed in on RVNC. Guggenheim reaffirmed a “neutral” rating on shares of Revance Therapeutics in a research note on Monday, August 12th. William Blair restated a “market perform” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. HC Wainwright reaffirmed a “neutral” rating and issued a $6.60 target price on shares of Revance Therapeutics in a report on Friday. Piper Sandler lowered Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research note on Friday. Nine analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, Revance Therapeutics has a consensus rating of “Hold” and an average price target of $9.66.

Revance Therapeutics Stock Down 36.0 %

NASDAQ RVNC opened at $3.70 on Friday. Revance Therapeutics has a twelve month low of $2.30 and a twelve month high of $9.74. The business has a 50-day moving average price of $5.66 and a 200-day moving average price of $4.42. The firm has a market cap of $387.85 million, a price-to-earnings ratio of -1.92 and a beta of 0.95.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $59.88 million during the quarter, compared to analyst estimates of $67.73 million. Research analysts expect that Revance Therapeutics will post -1.53 EPS for the current fiscal year.

Institutional Investors Weigh In On Revance Therapeutics

Institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets raised its holdings in Revance Therapeutics by 342.1% during the 1st quarter. BNP Paribas Financial Markets now owns 211,695 shares of the biopharmaceutical company’s stock valued at $1,042,000 after buying an additional 163,809 shares during the period. Swiss National Bank lifted its holdings in shares of Revance Therapeutics by 18.2% in the 1st quarter. Swiss National Bank now owns 194,650 shares of the biopharmaceutical company’s stock worth $958,000 after acquiring an additional 30,000 shares during the last quarter. NorthRock Partners LLC bought a new stake in shares of Revance Therapeutics in the 1st quarter worth about $151,000. Inspire Investing LLC boosted its stake in shares of Revance Therapeutics by 68.1% during the 1st quarter. Inspire Investing LLC now owns 73,160 shares of the biopharmaceutical company’s stock worth $360,000 after purchasing an additional 29,645 shares during the period. Finally, Blair William & Co. IL grew its holdings in Revance Therapeutics by 3.6% during the 1st quarter. Blair William & Co. IL now owns 329,267 shares of the biopharmaceutical company’s stock valued at $1,620,000 after purchasing an additional 11,318 shares during the last quarter. 97.70% of the stock is owned by institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.